LAVAL, Quebec, Sept. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer; Linda LaGorga, senior vice president, Finance, and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications; are scheduled to participate at the Deutsche Bank 25th Annual Leveraged Finance Conference in Scottsdale, Ariz. on Oct. 4, 2017 at 8:00 a.m. MST (11:00 a.m. EDT).
A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at: http://ir.valeant.com/events-and-presentations/2017.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
View original content:http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-deutsche-bank-25th-annual-leveraged-finance-conference-300524740.html
SOURCE Valeant Pharmaceuticals International, Inc.
